PL1715890T3 - CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową - Google Patents
CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycowąInfo
- Publication number
- PL1715890T3 PL1715890T3 PL05713358T PL05713358T PL1715890T3 PL 1715890 T3 PL1715890 T3 PL 1715890T3 PL 05713358 T PL05713358 T PL 05713358T PL 05713358 T PL05713358 T PL 05713358T PL 1715890 T3 PL1715890 T3 PL 1715890T3
- Authority
- PL
- Poland
- Prior art keywords
- diabetic nephropathy
- microalbuminuria
- ctgf
- therapy
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54412104P | 2004-02-11 | 2004-02-11 | |
| US56101804P | 2004-04-08 | 2004-04-08 | |
| US57840104P | 2004-06-09 | 2004-06-09 | |
| US62080204P | 2004-10-20 | 2004-10-20 | |
| PCT/US2005/004367 WO2005077413A1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of diabetic nephropathy |
| EP05713358A EP1715890B1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1715890T3 true PL1715890T3 (pl) | 2009-01-30 |
Family
ID=34865408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05713358T PL1715890T3 (pl) | 2004-02-11 | 2005-02-11 | CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050214294A1 (pl) |
| EP (2) | EP1977762A1 (pl) |
| CN (1) | CN101884789A (pl) |
| AT (1) | ATE400297T1 (pl) |
| AU (1) | AU2005212371B2 (pl) |
| CA (1) | CA2555789A1 (pl) |
| DE (1) | DE602005008013D1 (pl) |
| DK (1) | DK1715890T3 (pl) |
| ES (1) | ES2311973T3 (pl) |
| IL (1) | IL177437A (pl) |
| NZ (1) | NZ549784A (pl) |
| PL (1) | PL1715890T3 (pl) |
| PT (1) | PT1715890E (pl) |
| WO (1) | WO2005077413A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2342280A1 (en) * | 1998-09-08 | 2000-03-16 | Henry Ford Health System | Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| EP1885756A2 (en) | 2005-05-05 | 2008-02-13 | Fibrogen, Inc. | Vascular disease therapies |
| US8372886B2 (en) * | 2005-12-22 | 2013-02-12 | Kiacta Sarl | Treatment of renal disorders, diabetic nephropathy and dyslipidemias |
| MX2009006768A (es) * | 2006-12-22 | 2009-08-31 | Bellus Health Int Ltd | Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes. |
| JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| SI2670411T1 (sl) | 2011-02-02 | 2019-06-28 | Excaliard Pharmaceuticals, Inc. | Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin |
| KR102339724B1 (ko) | 2013-11-28 | 2021-12-17 | 씨에스엘 리미티드 | 신장병증의 치료 방법 |
| CN111033637B (zh) | 2017-08-08 | 2023-12-05 | 费森尤斯医疗保健控股公司 | 用于治疗和评估慢性肾脏疾病的进程的系统和方法 |
| CN112512532B (zh) * | 2018-07-31 | 2024-11-08 | 雷莫内克斯生物制药有限公司 | 用于抑制ctgf表达的组合物 |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| CN109453191A (zh) * | 2018-12-06 | 2019-03-12 | 郑州大学第附属医院 | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 |
| BR112021023669A2 (pt) * | 2019-06-04 | 2022-03-29 | Jiangsu Hengrui Medicine Co | Anticorpo do fator de crescimento de tecido anti-conjuntivo e aplicação do mesmo |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5876730A (en) | 1997-08-07 | 1999-03-02 | Childrens Hospital Research Foundation | Heparin-binding growth factor (HBGF) polypeptides |
| WO1999033878A1 (en) | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| AU4976599A (en) | 1998-07-08 | 2000-02-01 | Fibrogen, Inc. | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
| CA2342280A1 (en) * | 1998-09-08 | 2000-03-16 | Henry Ford Health System | Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| AU765133B2 (en) | 1998-11-06 | 2003-09-11 | Fibrogen, Inc. | Connective tissue growth factor (CTGF) and methods of use |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| CN1170849C (zh) * | 1998-12-14 | 2004-10-13 | 迈阿密大学 | 结缔组织生长因子片段及其方法和用途 |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| ATE526041T1 (de) * | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| WO2003092584A2 (en) | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| WO2005038013A1 (en) | 2003-10-07 | 2005-04-28 | Isis Pharmaceuticals, Inc. | Artisense oligonucleotides optimized for kidney targeting |
-
2005
- 2005-02-11 AU AU2005212371A patent/AU2005212371B2/en not_active Ceased
- 2005-02-11 CA CA002555789A patent/CA2555789A1/en not_active Abandoned
- 2005-02-11 DK DK05713358T patent/DK1715890T3/da active
- 2005-02-11 US US11/057,323 patent/US20050214294A1/en not_active Abandoned
- 2005-02-11 EP EP08011905A patent/EP1977762A1/en not_active Withdrawn
- 2005-02-11 NZ NZ549784A patent/NZ549784A/en unknown
- 2005-02-11 DE DE602005008013T patent/DE602005008013D1/de not_active Expired - Lifetime
- 2005-02-11 ES ES05713358T patent/ES2311973T3/es not_active Expired - Lifetime
- 2005-02-11 WO PCT/US2005/004367 patent/WO2005077413A1/en not_active Ceased
- 2005-02-11 EP EP05713358A patent/EP1715890B1/en not_active Expired - Lifetime
- 2005-02-11 PT PT05713358T patent/PT1715890E/pt unknown
- 2005-02-11 AT AT05713358T patent/ATE400297T1/de active
- 2005-02-11 CN CN2010102312546A patent/CN101884789A/zh active Pending
- 2005-02-11 PL PL05713358T patent/PL1715890T3/pl unknown
-
2006
- 2006-08-10 IL IL177437A patent/IL177437A/en active IP Right Grant
-
2010
- 2010-06-03 US US12/802,373 patent/US8314059B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977762A1 (en) | 2008-10-08 |
| WO2005077413A1 (en) | 2005-08-25 |
| NZ549784A (en) | 2008-06-30 |
| DE602005008013D1 (de) | 2008-08-21 |
| US8314059B2 (en) | 2012-11-20 |
| EP1715890B1 (en) | 2008-07-09 |
| PT1715890E (pt) | 2008-10-17 |
| ES2311973T3 (es) | 2009-02-16 |
| US20100291098A1 (en) | 2010-11-18 |
| CN101884789A (zh) | 2010-11-17 |
| CA2555789A1 (en) | 2005-08-25 |
| DK1715890T3 (da) | 2008-11-17 |
| US20050214294A1 (en) | 2005-09-29 |
| AU2005212371B2 (en) | 2010-05-13 |
| AU2005212371A1 (en) | 2005-08-25 |
| ATE400297T1 (de) | 2008-07-15 |
| IL177437A0 (en) | 2006-12-10 |
| EP1715890A1 (en) | 2006-11-02 |
| HK1095762A1 (en) | 2007-05-18 |
| IL177437A (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2006298A3 (en) | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| PL1715890T3 (pl) | CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową | |
| WO2009050506A3 (en) | Combination 059 | |
| HRP20130707T1 (en) | Compositions and uses for treating multiple sclerosis | |
| TW200740804A (en) | Glucokinase activators | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| PL1615952T3 (pl) | Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2 | |
| CR8380A (es) | Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos | |
| SG170775A1 (en) | 2 -aminopyridine analogs as glucokinase activators | |
| WO2010059969A3 (en) | Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer | |
| CY1112397T1 (el) | Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου | |
| GB2442915B (en) | Perylenequinone derivatives and uses thereof | |
| WO2005082386A3 (en) | Manganese and iron based compounds for elastogenesis and connective tissue treatment | |
| WO2006117660A3 (en) | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins | |
| GB0416508D0 (en) | Therapeutic agents | |
| WO2004004653A3 (en) | Methods for treating psychosis associated with interferon-alpha therapy | |
| WO2006128125A3 (en) | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases | |
| MX2007013834A (es) | Terapias de enfermedades vasculares. | |
| SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice | |
| GB0410238D0 (en) | Therapeutic agents | |
| MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. | |
| WO2006004774A3 (en) | Laulimalide analogues as therapeutic agents | |
| AU2003240254A8 (en) | Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac | |
| ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) |